Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma

Thrombosis and Haemostasis

Volumn 94, Issue 1, 2005, Pages 75-81

  Nardulli, Marina ^a,c   Durlach, Vincent ^b   Pepe, Gabriella ^a   Anglés Cano, Eduardo ^c  

^a UNIVERSITY OF BARI   (Italy)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Apolipoprotein(a); Fibrinolytic activity; Homocysteine; Lipoprotein(a); Plasminogen

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; FIBRIN; HOMOCYSTEINE; LIGAND; LIPOPROTEIN A; PLASMINOGEN;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; FIBRINOLYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LIGAND BINDING; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RISK FACTOR; THROMBOSIS;

ANTIFIBRINOLYTIC AGENTS; BLOTTING, WESTERN; CELL LINE; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HOMOCYSTEINE; HUMANS; IMMUNOBLOTTING; LIGANDS; LIPOPROTEIN(A); PHENOTYPE; PLASMINOGEN; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 22144471564     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-12-0808     Document Type: Article

References (42)

1. Evans RW, Shaten BJ, Hempel JD et al. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
2. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
3. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-43.
4. Foody JM, Milberg JA, Robinson K et al. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493-9.
5. McLean JW, Tomlinson JE, Kuang WJ et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
6. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-56.
7. Plow EF, Freaney DE, Plescia J et al. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-20.
8. Brunner C, Lobentanz EM, Petho-Schramm A et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996; 271: 32403-10.
9. Hoover-Plow JL, Miles LA, Fless GM et al. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry 1993; 32: 13681-7.
10. Ernst A, Helmhold M, Brunner C et al. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270: 6227-34.
11. Edelstein C, Mandala M, Pfaffinger D et al. Determinants of lipoprotein(a) assembly: a study of wildtype and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995; 34: 16483-92.
12. Eaton DL, Fless GM, Kohr WJ et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A 1987; 84: 3224-8.
13. Hajjar KA, Gavish D, Breslow JL et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
14. Boonmark NW, Lou XJ, Yang ZJ et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997; 100: 558-64.
15. Hughes SD, Lou XJ, Ighani S et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997; 100: 1493-500.
16. Miles LA, Fless GM, Scanu AM et al. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 1995; 73: 458-65.
17. Rouy D, Grailhe P, Nigon F et al. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991; 11: 629-38.
18. Hervio L, Durlach V, Girard-Globa A et al. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995; 34: 13353-8.
19. Hervio L, Girard-Globa A, Durlach V et al. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996; 26: 411-7.
20. Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100: 1154-60.
21. Kang C, Dominguez M, Loyau S et al. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002; 22: 1232-8.
22. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992; 89: 10193-7.
23. Angles-Cano E, Loyau S, Cardoso-Saldana G, Couderc R et al. A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping. J Lipid Res 1999; 40: 354-9.
24. Sorell L, Rojas G, Rodriguez M et al. A sandwich ELISA based on anti-apo(a) and anti-apo B monoclonal antibodies for lipoprotein(a) measurement. Clin Chim Acta 1995; 236: 59-70.
25. Tsurapa G, Ho-Tin-Noe B, Angles-Cano E et al. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains. J Biol Chem 2003; 278: 37154-9.
26. Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-8.
27. Soulat T, Loyau S, Baudouin V et al. Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol 2000; 20: 575-84.
28. de la Pena-Diaz A, Cardoso-Saldana G, Zamora-Gonzalez J et al. Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. Eur J Clin Invest 2003; 33: 99-105.
29. Soulat T, Loyau S, Baudouin V et al. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a). Thromb Haemost 1999; 82: 121-7.
30. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 1991; 49: 1063-74.
31. Togawa T, Sengupta S, Chen H et al. Mechanisms for the formation of protein-bound homocysteine in human plasma. Biochem Biophys Res Commun 2000; 277: 668-74.
32. Sengupta S, Chen H, Togawa T et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001; 276: 30111-7.
33. Ventura P, Panini R, Rosa MC et al. Relevance of different apolipoprotein content in binding of homocysteine to plasma lipoproteins. Nutr Metab Cardiovasc Dis 2003; 13: 218-26.
34. Majors AK, Sengupta S, Willard B et al. Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol 2002; 22: 1354-9.
35. Cauza E, Kletzmaier J, Bodlaj G et al. Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003; 18: 1568-72.
36. Herrmann W, Quast S, Ellgass A et al. An increased serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine. Nephron 2000; 85: 41-9.
37. Sengupta S, Wehbe C, Majors AK et al. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 2001; 276: 46896-904.
38. Hajjar KA, Mauri L, Jacovina AT et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-93.
39. Bescond A, Augier T, Chareyre C et al. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999; 263: 498-503.
40. Undas A, Williams EB, Butenas S et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276: 4389-97.
41. Hopkins PN, Wu LL, Hunt SC et al. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2783-92.
42. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91-101.